Caption Management’s Roivant Sciences ROIV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-609,200
Closed -$13.2M 1995
2025
Q4
$13.2M Sell
609,200
-87,800
-13% -$1.73M 0.09% 257
2025
Q3
$10.5M Sell
697,000
-1,303,000
-65% -$16.1M 0.08% 267
2025
Q2
$22.5M Buy
+2,000,000
New +$21.7M 0.25% 79
2024
Q1
Sell
-149,900
Closed -$1.68M 1619
2023
Q4
$1.68M Sell
149,900
-169,400
-53% -$1.65M 0.02% 662
2023
Q3
$3.73M Buy
+319,300
New +$3.61M 0.06% 399

Other funds holding ROIV

Caption Management's ROIV Position: Q1 2026 in Review

Caption Management increased its Roivant Sciences (ROIV) stake by 37% in Q1 2026, buying an estimated $1.51M and bringing the position to 219,800 shares worth $6.09M. The position accounts for 0.04% of the portfolio, ranked #475.

Caption Management first reported a position in ROIV in Q3 2023 and has held it in 8 quarters since. 439 funds tracked by Wall St. Rank hold ROIV as of Q1 2026.

  • Caption Management held 219,800 shares of Roivant Sciences worth $6.09M as of Q1 2026.
  • Caption Management bought 58,813 Roivant Sciences shares in Q1 2026, an estimated $1.51M.
  • Roivant Sciences made up 0.04% of Caption Management's portfolio in Q1 2026, its #475 holding.
  • Caption Management first reported a position in Roivant Sciences in Q3 2023 and has held it in 8 quarters since.
  • 439 funds tracked by Wall St. Rank held Roivant Sciences as of Q1 2026.

Based on Caption Management's 13F filing for Q1 2026, filed 15 May 2026.